a year ago

Nebu-Flow Secures $5.9 Million to Advance Respiratory Drug Delivery

  • Nebu-Flow, a Glasgow, Scotland-based provider of a nebulizer platform, raised an additional $5.9 million in funding led by SCVC, with participation from Scottish Enterprise, Foresight WAE Technology, SIS Ventures, Ascension, and Conduit EIS Impact Fund

  • The company intends to use the funds to accelerate the development of inhaled drugs for patients with respiratory disorders

  • Nebu-Flow is developing a new generation of nebulisers to enable inhalation delivery of life-changing treatments.

      • ProblemHealthcare

      "Currently, delivering medication to patients with respiratory issues through inhalation is often ineffective due to the limitations of existing nebulizer technology. This results in inconsistent drug delivery and suboptimal treatment outcomes for patients."

      Solution

      "Nebu-Flow is developing a new generation of nebulizers that utilize advanced technology to achieve precise and effective delivery of inhaled medications. This aims to improve patient outcomes and reduce the limitations of existing methods."

      Covered on